{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:47:18Z","timestamp":1792522038067,"version":"4.5.0"},"reference-count":119,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2019,6,22]],"date-time":"2019-06-22T00:00:00Z","timestamp":1561161600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AG046153, AI104034 and NS106305"],"award-info":[{"award-number":["AG046153, AI104034 and NS106305"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Neurodegenerative diseases, including Alzheimer\u2019s disease (AD), Parkinson\u2019s disease (PD), Huntington\u2019s disease (HD), and amyotrophic lateral sclerosis (ALS), currently affect more than 6 million people in the United States. Unfortunately, there are no treatments that slow or prevent disease development and progression. Regardless of the underlying cause of the disorder, age is the strongest risk factor for developing these maladies, suggesting that changes that occur in the aging brain put it at increased risk for neurodegenerative disease development. Moreover, since there are a number of different changes that occur in the aging brain, it is unlikely that targeting a single change is going to be effective for disease treatment. Thus, compounds that have multiple biological activities that can impact the various age-associated changes in the brain that contribute to neurodegenerative disease development and progression are needed. The plant-derived flavonoids have a wide range of activities that could make them particularly effective for blocking the age-associated toxicity pathways associated with neurodegenerative diseases. In this review, the evidence for beneficial effects of multiple flavonoids in models of AD, PD, HD, and ALS is presented and common mechanisms of action are identified. Overall, the preclinical data strongly support further investigation of specific flavonoids for the treatment of neurodegenerative diseases.<\/jats:p>","DOI":"10.3390\/ijms20123056","type":"journal-article","created":{"date-parts":[[2019,6,24]],"date-time":"2019-06-24T02:37:40Z","timestamp":1561343860000},"page":"3056","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":206,"title":["The Potential of Flavonoids for the Treatment of Neurodegenerative Diseases"],"prefix":"10.3390","volume":"20","author":[{"given":"Pamela","family":"Maher","sequence":"first","affiliation":[{"name":"Salk Institute for Biological Studies, La Jolla, CA 92037, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,6,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1172\/JCI200317522","article-title":"Neurodegeneration: What is it and where are we?","volume":"111","author":"Przedborski","year":"2003","journal-title":"J. Clin. Investig."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1177\/2045125317739818","article-title":"Frontotemporal dementia: Latest evidence and clinical implications","volume":"8","author":"Young","year":"2018","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"ref_3","unstructured":"(2019, June 21). Available online: https:\/\/www.alz.org\/alzheimers-dementia\/facts-figures."},{"key":"ref_4","unstructured":"(2019, June 21). Available online: https:\/\/parkinson.org\/Understanding-Parkinsons\/Statistics."},{"key":"ref_5","unstructured":"(2019, June 21). Available online: https:\/\/rarediseases.org\/rare-diseases\/huntingtons-disease."},{"key":"ref_6","unstructured":"(2019, June 21). Available online: https:\/\/www.cdc.gov\/mmwr\/volumes\/67\/wr\/mm6707a3.htm."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1021\/cn500051h","article-title":"Back to the future with phenotypic screening","volume":"5","author":"Prior","year":"2014","journal-title":"ACS Chem. Neurosci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nature08983","article-title":"Neural mechanisms of ageing and cognitive decline","volume":"464","author":"Bishop","year":"2010","journal-title":"Nature"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.4155\/fmc.12.109","article-title":"An alternative approach to drug discovery for Alzheimer\u2019s disease dementia","volume":"4","author":"Schubert","year":"2012","journal-title":"Future Med. Chem."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"1Schubert, D., Currais, A., Goldberg, J., Finley, K., Petrascheck, M., and Maher, P. (2018). Geroneuroprotectors: Effective geroprotectors for the brain. Trends Pharmacol. Sci., 39, 1004\u20131007.","DOI":"10.1016\/j.tips.2018.09.008"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.tips.2014.02.001","article-title":"Insights into drug discovery from natural medicines using reverse pharmacokinetics","volume":"35","author":"Hao","year":"2014","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/clpt.2012.236","article-title":"Phenotypic vs. target-based drug discovery for firrst-in-class medicines","volume":"93","author":"Swinney","year":"2013","journal-title":"Clin. Pharm. Therap."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3390\/metabo2020303","article-title":"A historical overview of natural products in drug discovery","volume":"2","author":"Dias","year":"2012","journal-title":"Metabolites"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"47","DOI":"10.5661\/bger-28-47","article-title":"Plant natural products: History, limitations and the potential of cambial meristematic cells","volume":"28","author":"Yun","year":"2013","journal-title":"Biotech. Gen. Eng. Rev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/j.biopha.2018.10.086","article-title":"Phytochemicals and cognitive health: Are flavonoids doing the trick?","volume":"109","author":"Bakoyiannis","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1017\/S1368980009992990","article-title":"Flavonoid intake and disability-adjuested life years due to Alzheimer\u2019s and related dementias: A population-based study involving twenty-three developed countries","volume":"13","author":"Beking","year":"2010","journal-title":"Public Health Nutr."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1023\/A:1007614613771","article-title":"Intake of flavonoids and risk of dementia","volume":"16","author":"Commenges","year":"2000","journal-title":"Eur. J. Epidemiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1212\/WNL.0b013e31824f7fc4","article-title":"Habitual intake of dietary flavonoids and risk of Parkinson\u2019s disease","volume":"78","author":"Gao","year":"2012","journal-title":"Neurology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.tips.2012.08.002","article-title":"Target-based selection of flavonoids for neurodegenerative disorders","volume":"33","author":"Jones","year":"2012","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2174\/1871527317666171221110139","article-title":"Literature evidence and ARRIVE assessment on neuroprotective effects of flavonols in neurodegenerative diseases\u2019 models","volume":"17","author":"Duarte","year":"2018","journal-title":"CNS Neurolog. Dis. Drug Targets"},{"key":"ref_21","first-page":"7043213","article-title":"Flavonoids as therapeutic agents in Alzheimer\u2019s and Parkinson\u2019s diseases: A systematice review of preclinical evidences","volume":"2018","author":"Diniz","year":"2018","journal-title":"Oxid. Med. Cell. Longev."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Kujawska, M., and Jodynis-Liebert, J. (2018). Polyphenols in Parkinson\u2019s disease: A systematic review of in vivo studies. Nutrients, 10.","DOI":"10.3390\/nu10050642"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.neubiorev.2017.01.004","article-title":"Mouse models of frontotemporal dementia: A comparison of phenotypes with clinical symptomatology","volume":"74","author":"Ahmed","year":"2017","journal-title":"Neurosc. Biobehav. Rev."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1126\/science.1132814","article-title":"A century of Alzheimer\u2019s disease","volume":"314","author":"Goedert","year":"2006","journal-title":"Science"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical diagnosis of Alzheimer\u2019s disease: Report of the NINCDS-ADRDA work group under the auspices of Department of Health and Humans Services Task Force on Alzheimer\u2019s disease","volume":"34","author":"McKhann","year":"1984","journal-title":"Neurology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1474-4422(05)70219-2","article-title":"Behavioral changes and psychological symptoms in dementia disorders","volume":"4","author":"McKeith","year":"2005","journal-title":"Lancet Neurol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3233\/JAD-2011-110986","article-title":"Strategies, development and pitfalls of therapeutic options for Alzheimer\u2019s disease","volume":"28","author":"Haas","year":"2012","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Rafil, M.S., and Aisen, P.S. (2009). Recent developments in Alzheimer\u2019s disease therapeutics. BMC Med., 7.","DOI":"10.1186\/1741-7015-7-7"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.trci.2017.04.005","article-title":"Phase II clinical trials of anti-amyloid \u03b2 antibodies: When is enough, enough?","volume":"3","author":"Gold","year":"2017","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_30","unstructured":"(2019, June 21). Available online: https:\/\/www.alzforum.org\/research-models\/alzheimers-disease."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/j.neurobiolaging.2006.06.021","article-title":"Is aging part of Alzheimer\u2019s disease, or is Alzheimer\u2019s disease part of aging?","volume":"28","author":"Swerdlow","year":"2007","journal-title":"Neurobiol. Aging"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/nn.4017","article-title":"The case for rejecting the amyloid cascade hypothesis","volume":"18","author":"Herrup","year":"2015","journal-title":"Nat. Neurosci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"917167","DOI":"10.5402\/2012\/917167","article-title":"Senescence-accelerated mice P8: A tool to study brain aging and Alzheimer\u2019s disease in a mouse model","volume":"2012","author":"Pallas","year":"2012","journal-title":"ISRN Cell Biol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.bbadis.2011.11.015","article-title":"The senescence accelerated mouse (SAMP8) as a model for oxidative stress and Alzheimer\u2019s disease","volume":"1822","author":"Morley","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.arr.2013.10.002","article-title":"The behavioral, pathological and therapeutic features of the senescence-accelerated mouse prone 8 strain as an Alzheimer\u2019s disease animal model","volume":"13","author":"Cheng","year":"2014","journal-title":"Ageing Res. Rev."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"937","DOI":"10.18632\/aging.100838","article-title":"A comprehensive multiomics approach toward understanding the relationship between aging and dementia","volume":"7","author":"Currais","year":"2015","journal-title":"Aging"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"898","DOI":"10.4161\/cc.28255","article-title":"Senescence-accelerated OXYS rats: A model of age-related cognitive decline with relevance to Alzheimer disease","volume":"13","author":"Stefanova","year":"2014","journal-title":"Cell Cycle"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/npp.2011.191","article-title":"7,8 Dihydroxyflavone, a small molecule TrkB agonist, reverses memory deficits and BACE1 elevation in a mouse model of Alzheimer\u2019s disease","volume":"37","author":"Devi","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/npp.2013.243","article-title":"7,8 Dihydroxyflavone prevents synaptic loss and memory deficits in a mouse model of Alzheimer\u2019s disease","volume":"39","author":"Zhang","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2174\/1567205012666141218124243","article-title":"No significant effect of 7,8 dihydroxyflavone on APP processing and Alzheimer-associated phenotypes","volume":"12","author":"Zhou","year":"2015","journal-title":"Curr. Alzheimer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"9949","DOI":"10.3390\/molecules18089949","article-title":"Neuroprotective, anti-amyloidgenic and neurotrophic effects of apigenin in an Alzheimer\u2019s disease model","volume":"18","author":"Zhao","year":"2013","journal-title":"Molecules"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1124\/jpet.108.140293","article-title":"Nobiletin, a citrus flavonoid, improves memory impairment and Abeta pathology in a transgenic model of Alzheimer\u2019s disease","volume":"326","author":"Onozuka","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.bbr.2015.04.028","article-title":"Nobiletin, a citrus flavonoid, improves cognitive impairment and reduces soluble A\u03b2 levels in a triple transgenic mouse model of Alzheimer\u2019s disease (3XTg-AD)","volume":"289","author":"Nakajima","year":"2015","journal-title":"Behav. Brain Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.bbr.2013.05.025","article-title":"Nobiletin, a citrus flavonoid, ameliorates cognitive impairment, oxidative burden and hyperphosphorylation of tau in senescence-accelerated mouse","volume":"250","author":"Nakajima","year":"2013","journal-title":"Behav. Brain Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/jnr.23244","article-title":"Baicalein reduces b-amyloid and promotes nonamyloidgenic amyloid precursor protein processing in an Alzheimer\u2019s disease transgenic mouse model","volume":"91","author":"Zhang","year":"2013","journal-title":"J. Neurosci. Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/acel.12185","article-title":"Modulation of p25 and inflammatory pathways by fisetin maintains cognitive function in Alzheimer\u2019s disease transgenic mice","volume":"13","author":"Currais","year":"2014","journal-title":"Aging Cell"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1093\/gerona\/glx104","article-title":"Fisetin reduces the impact of aging on behavior and physiology in the rapidly aging SAMP8 mouse","volume":"73","author":"Currais","year":"2018","journal-title":"J. Gerentol. Biol. Sci. Med. Sci."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1007\/s12035-016-9795-4","article-title":"Neuroprotective effect of fisetin against amyloid-beta-induced cognitive\/synaptic dysfunction, neuroinflammation and neurodegeneration in mice","volume":"54","author":"Ahmad","year":"2017","journal-title":"Mol. Neurobiol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.conb.2004.04.001","article-title":"Mitogen-activated protein kinases in synaptic plasticity and memory","volume":"14","author":"Sweatt","year":"2004","journal-title":"Curr. Opin. Neurobiol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1111\/j.1471-4159.2004.02563.x","article-title":"Induction of PC12 cell differentiation by flavonoids is dependent upon extracellular signal-regulated kinase activation","volume":"90","author":"Sagara","year":"2004","journal-title":"J. Neurochem."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.lfs.2019.03.055","article-title":"Molecular mechanisms underlying protective role of quercetin in attenuating Alzheimer disease","volume":"224","author":"Zaplatic","year":"2019","journal-title":"Life Sci."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ijpharm.2016.11.061","article-title":"Effect of the oral administration of nanoencapsulated quercetin on a mouse model of Alzheimer\u2019s disease","volume":"517","author":"Puerta","year":"2017","journal-title":"Int. J. Pharmaceut."},{"key":"ref_53","first-page":"134","article-title":"The flavonoid quercetin ameliorates Alzheimer\u2019s disease pathology and protects cognitive and emotional function in aged triple transgenic Alzheimer\u2019s disease model mice","volume":"93","author":"Osorio","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.toxlet.2013.10.010","article-title":"Rutin activates the MAPK pathway and BDNF gene expression on beta-amyloid induce neurotoxicity in rats","volume":"224","author":"Moghbelinejad","year":"2014","journal-title":"Toxicol. Lett."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"6490","DOI":"10.1007\/s12035-016-0136-4","article-title":"Anthocyanin-loaded PEG-gold nanoparticles enhanced the neuroprotection of anthocyanins in A\u03b21-42 mouse model of Alzheimer\u2019s disease","volume":"54","author":"Ali","year":"2017","journal-title":"Mol. Neurobiol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1016\/j.nano.2017.06.022","article-title":"Enhanced neuroprotection of anthocyanin-loaded PEG-gold nanoparticles against A\u03b21-42-induced neuroinflammation and neurodegeneration via the NF-kB\/JNK\/GSK3\u03b2 signaling pathway","volume":"13","author":"Kim","year":"2017","journal-title":"Nanomed. Nanotech. Biol. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3233\/JAD-140981","article-title":"Beneficial effects of dietary EGCG and voluntary exercise on behavior in an Alzheimer\u2019s disease mouse model","volume":"44","author":"Walker","year":"2015","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1097\/WNR.0000000000000803","article-title":"(\u2212)-Epigallocatechin-3-gallate ameliorates memory impairment and rescues the abnormal synpatic protein levels in the frontal cortex and hippocampus on a mouse model of Alzheimer\u2019s disease","volume":"28","author":"Guo","year":"2017","journal-title":"Neuroreport"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Ide, K., Matsuoka, N., Yamada, H., Furushima, D., and Kawakami, K. (2018). Effects of tea catechins on Alzheimer\u2019s disease: Recent updates and perspectives. Molecules, 23.","DOI":"10.3390\/molecules23092357"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.bbr.2014.12.012","article-title":"Hesperidin ameliorates behavioral impairments and neuropathology of transgenic APP\/PS1 mice","volume":"281","author":"Li","year":"2015","journal-title":"Behav. Brain Res."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Hajialyani, M., Farzaei, M.H., Echeverria, J., Nabavi, S.M., Uriarte, E., and Sobarzo-Sanchez, E. (2019). Hesperidin as a neuroprotective agent: A review of animal and clinical evidence. Molecules, 24.","DOI":"10.3390\/molecules24030648"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"174","DOI":"10.4103\/bc.bc_13_18","article-title":"Effects of three flavonoids from an ancient Chinese medicine Radix puerariae on geriatric diseases","volume":"4","author":"Zhang","year":"2018","journal-title":"Brain Circ."},{"key":"ref_63","first-page":"S40","article-title":"Parkinson\u2019s disease","volume":"14","author":"Weintraub","year":"2008","journal-title":"Am. J. Manag. Care"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"a008888","DOI":"10.1101\/cshperspect.a008888","article-title":"Genetics of Parkinson\u2019s disease","volume":"2","author":"Klein","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s00441-004-0954-y","article-title":"Neuronal pathology in Parkinson\u2019s disease","volume":"318","author":"Schulz","year":"2004","journal-title":"Cell Tissue Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"a009316","DOI":"10.1101\/cshperspect.a009316","article-title":"A guide to neurotoxic animal models of Parkinson\u2019s disease","volume":"1","author":"Tieu","year":"2011","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3389\/fnana.2014.00155","article-title":"Parkinson\u2019s disease: Animal models and dopaminergic cell vulnerability","volume":"8","author":"Blesa","year":"2014","journal-title":"Front. Neuroanat."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.jep.2016.10.040","article-title":"Baicalein attenuates \u03b1-synuclein aggregation, inflammasome activation and autophagy in the MPP+-treated nigrostriatal dopaminergic system in vivo","volume":"194","author":"Hung","year":"2016","journal-title":"J. Ethnopharmcol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.neulet.2008.05.116","article-title":"Neuroprotective effect of baicalein against MPTP neurotoxicity: Behavioral, biochemical and immunohistochemical profile","volume":"441","author":"Cheng","year":"2008","journal-title":"Neurosci. Lett."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"9968","DOI":"10.1038\/s41598-017-07442-y","article-title":"Therapeutic effects of baicalein on rotenone-induced Parkinson\u2019s disease through protecting mitochondrial function and biogenesis","volume":"7","author":"Zhang","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.neulet.2016.03.042","article-title":"7,8 Dihydroxyflavone protects 6-OHDA and MPTP induced dpaminergic neurons degeneration through activation of TrkB in rodents","volume":"620","author":"Luo","year":"2016","journal-title":"Neurosci. Lett."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/cns.12555","article-title":"7,8 Dihydroxyflavone ameliorates motor deficits via supressing a-synuclein expression and oxidative stress in the MPTP-indiuced mouse model of Parkinson\u2019s disease","volume":"22","author":"Li","year":"2016","journal-title":"CNS Neurosci. Ther."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.neuroscience.2014.12.080","article-title":"Intervention with 7,8 dihydorxyflavone blocks further striatal terminal loss and restores motor deficits in a progressive mouse model of Parkinson\u2019s disease","volume":"290","author":"Sconce","year":"2015","journal-title":"Neuroscience"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"34339","DOI":"10.1038\/srep34339","article-title":"Neuroprotective effects of 7,8, dihydroxyflavone on midbrain dopaminergic neurons in MPP+-treated monkeys","volume":"6","author":"He","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.cbi.2017.03.016","article-title":"Protective role of apigenin on rotenone induced rat model of Parkinson\u2019s disease: Suppression of neuroinflammation and oxidative stress mediated apoptosis","volume":"269","author":"Anusha","year":"2017","journal-title":"Chem.-Biol. Interactions"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.neuropharm.2014.07.012","article-title":"Neuroprotective and neurotrophic effects of apigenin and luteolin in MPTP induced parkinsonism in mice","volume":"86","author":"Patil","year":"2014","journal-title":"Neuropharmacology"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.cbi.2017.10.019","article-title":"Protective role of chrysin on 6-hydroxydopamine-induced neurodegeneration a mouse model of Parkinson\u2019s disease: Involvement of neuroinflammation and neurotrophins","volume":"279","author":"Goes","year":"2018","journal-title":"Chem.-Biol. Interact."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1089\/jmf.2014.3241","article-title":"Nobiletin protects dopaminergic neurons in the 1-mehtyl-4-phenylpyridinium rat model of Parkinson\u2019s disease","volume":"18","author":"Jeong","year":"2015","journal-title":"J. Med. Food"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/jnr.23764","article-title":"Neuroprotective and anti-inflammatory effects of morin in a murine model of Parkinson\u2019s disease","volume":"94","author":"Lee","year":"2016","journal-title":"J. Neurosci. Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1080\/10715760500233113","article-title":"Neuroprotective properties of the natural phenolic antioxidants curcumin and naringenin but not quercetin and fisetin in a 6-OHDA model of Parkinson\u2019s disease","volume":"39","author":"Zbarsky","year":"2005","journal-title":"Free Rad. Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2131\/jts.38.25","article-title":"Effect of quercetin and desferriooxamine on 6-hydroxydopamine (6-OHDA) induced neurotoxicity in striatum of rats","volume":"38","author":"Haleagrahara","year":"2013","journal-title":"J. Toxicol. Sci."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.neuroscience.2013.01.032","article-title":"Quercetin up-regulates mitochondrial complex-I activity to protect against programmed cell death in rotenone model of Parkinson\u2019s disease in rats","volume":"236","author":"Karuppagounder","year":"2013","journal-title":"Neuroscience"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"928643","DOI":"10.1155\/2012\/928643","article-title":"Effect of quercetin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of Parkinson\u2019s disease","volume":"2012","author":"Lv","year":"2012","journal-title":"Evid.-Based Complemen. Alternat. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/jnc.14033","article-title":"Molecular mechanisms underlying protective effects of quercetin agianst mitochondrial dysfunction and progressive dopaminergic neurodegeneration in cell culture and MitoPark transgenic mouse models of Parkinson\u2019s disease","volume":"141","author":"Ay","year":"2017","journal-title":"J. Neurochem."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"S185","DOI":"10.1016\/S1353-8020(09)70811-9","article-title":"The MitoPark Mouse-An animal model of Parkinson\u2019s diease with impaired respiratory chain function in dopamine neurons","volume":"1553","author":"Ekstrand","year":"2009","journal-title":"Parkinsonism Rel. Dis."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12640-011-9295-2","article-title":"Rutin protects dopaminergic neurons from oxidative stress in an animal model of Parkinson\u2019s disease","volume":"22","author":"Khan","year":"2012","journal-title":"Neurotox. Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1039\/C7FO00809K","article-title":"Protective effects of fisetin and other berry flavonoids in Parkinson\u2019s disease","volume":"8","author":"Maher","year":"2017","journal-title":"Food Func."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1248\/bpb.34.1291","article-title":"Neuroprotective effect of kaempferol against 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine-induced mouse model of Parkinson\u2019s disease","volume":"34","author":"Li","year":"2011","journal-title":"Biol. Pharm. Bull."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pbb.2013.05.012","article-title":"Catechin attenuates behavioral neurotoxicity induced by 6-OHDA in rats","volume":"110","author":"Teixeira","year":"2013","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.3945\/jn.117.255034","article-title":"Epigallocatechin gallate has a neurorescue effect in a mouse model of Parkinson Disease","volume":"147","author":"Xu","year":"2017","journal-title":"J. Nutr."},{"key":"ref_91","first-page":"276039","article-title":"Epicatechin reduces striatal MPP+-induce damage in rats through slight increases in SOD-Cu,Zu Activity","volume":"2015","author":"Montes","year":"2015","journal-title":"Oxid. Med. Cell. Longev."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1007\/s12640-018-9869-3","article-title":"Naringenin decreases a-synuclein expression and neuroinflammation in MPTP-induced Parkinson\u2019s disease model in mice","volume":"33","author":"Mani","year":"2018","journal-title":"Neurotox. Res."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s11064-015-1796-6","article-title":"Protective effect of oral hesperetin against unilateral striatal 6-hydorxydopamine damage in the rat","volume":"41","author":"Kiasalari","year":"2016","journal-title":"Neurochem. Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jnutbio.2015.10.013","article-title":"Naringin treatment induces neuroprotective effects in a mouse model of Parkinson\u2019s disease in vivo, but not enough to restore the lesioned dopaminergic system","volume":"28","author":"Kim","year":"2016","journal-title":"J. Nutr. Biochem."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.nut.2014.03.024","article-title":"Protective effect of hesperidin in a model of Parkinson\u2019s disease induced by 6-hydroxydopmaine in aged mice","volume":"30","author":"Antunes","year":"2014","journal-title":"Nutrition"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1007\/s00018-006-6242-0","article-title":"Huntington\u2019s disease: From huntingtin function and dysfunction to therapeutic strategies","volume":"63","author":"Zala","year":"2006","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3727\/000000007783464687","article-title":"Huntington\u2019s disease: Pathological mechanisms and therapeutic strategies","volume":"16","author":"Ramaswamy","year":"2007","journal-title":"Cell Transplant."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1042\/BJ20071619","article-title":"Huntington\u2019s disease: From pathology and genetics to potential therapeutics","volume":"412","author":"Imarisio","year":"2008","journal-title":"Biochem. J."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1111\/j.1460-9568.2008.06310.x","article-title":"Mechanisms of neurodegeneration in Huntington\u2019s disease","volume":"27","author":"Gil","year":"2008","journal-title":"Eur. J. Neurosci."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1002\/cpns.47","article-title":"Overview of Huntington\u2019s disease models: Neuropathological, molecular and behavioral differences","volume":"83","author":"Rebec","year":"2018","journal-title":"Curr. Protoc. Neurosci."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0149-7634(96)00027-9","article-title":"3-Nitropropionic acid animal model and Huntington\u2019s disease","volume":"21","author":"Borlongan","year":"1997","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.biopha.2016.09.070","article-title":"Chrysin exerts neuroprotective effects against 3-nitropropionic acid induced behavioral despair-mitochondrial dysfunction and striatal apoptosis via upregulating Bcl-2 gene and downregulating Bax-Bad gnes in male wistar rats","volume":"84","author":"Thangarajan","year":"2016","journal-title":"Biomed. Pharmacother."},{"key":"ref_103","first-page":"3144","article-title":"7,8 Dihydroxyflavone ameliorates cognitive and motor deficits in a Huntington\u2019s disease mouse model through specific activation of the PLC\u03b31 pathway","volume":"26","author":"Barriga","year":"2017","journal-title":"Hum. Mol. Gen."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/hmg\/ddq460","article-title":"ERK activation by the polyphenols fisetin and resveratrol provides neuroprotection in multiple models of Huntington\u2019s disease","volume":"20","author":"Maher","year":"2011","journal-title":"Hum. Mol. Gen."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.bbadis.2012.11.018","article-title":"Quercetin supplementation is effective in improving mitochondrial dysfunctions induced by 3-nitropropionic acid: Implications in Huntington\u2019s disease","volume":"1832","author":"Sandhir","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/cns.12189","article-title":"Quercetin improves behavioral deficiencies, restores astrocytes and microglia, and reduces serotonin metabolism in 3-nitropropionic acid-induced rat model of Huntington\u2019s disease","volume":"20","author":"Chakraborty","year":"2014","journal-title":"CNS Neurosci. Ther."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s11011-016-9929-4","article-title":"Effect of rutin against a mitochondrial toxin, 3-nitropropionic acid induced biochemical, behavioral and histological alterations-a pilot study on Huntington\u2019s disease model in rats","volume":"32","author":"Suganya","year":"2017","journal-title":"Metab. Brain Dis."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.1471-4159.2009.06331.x","article-title":"Kaempferol protects against rat striatal degeneration induced by 3-nitropropionic acid","volume":"111","author":"Lagoa","year":"2009","journal-title":"J. Neurochem."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.neuro.2012.07.007","article-title":"Potential neuroprotective effects of hesperidin on 3-nitropropionic acid-induced neurotoxicity in rats","volume":"33","author":"Menze","year":"2012","journal-title":"Neurotoxicology"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.neuropharm.2016.01.007","article-title":"Genistein improves sensorimotor gating: Mechanisms related to its neuroprotective effects on the striatum","volume":"105","author":"Menze","year":"2016","journal-title":"Neuropharmacology"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3233\/JHD-160204","article-title":"Therapeutic effects of anthocyanins and environmental enrichment in R6\/1 Huntongton\u2019s disease mice","volume":"5","author":"Kreilaus","year":"2016","journal-title":"J. Huntington\u2019s Dis."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"193","DOI":"10.4103\/1673-5374.244783","article-title":"Amytotrophic lateral sclerosis: A complex syndrome that needs an integrated research approach","volume":"14","author":"Riancho","year":"2019","journal-title":"Neural Regen. Res."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainres.2018.03.024","article-title":"Mouse models of ALS","volume":"1693","author":"Lutz","year":"2018","journal-title":"Brain Res."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/nrneurol.2015.65","article-title":"FTD and ALS-translating mouse studies into clinical trials","volume":"11","author":"Ittner","year":"2015","journal-title":"Nat. Rev. Neurol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.neulet.2014.02.058","article-title":"7,8 Dihydroxyflavone improves motor performance and enhances lower motor neuronal survival in a mouse model of amyotrophic lateral sclerosis","volume":"566","author":"Korkmaz","year":"2014","journal-title":"Neurosci. Lett."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.neuroscience.2018.03.008","article-title":"Fisetin exerts antioxidant and neuroprotective effects in mulitple mutant hSOD1 modles of amyotrophic lateral sclerosis by activating ERK","volume":"379","author":"Wang","year":"2018","journal-title":"Neuroscience"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1007\/s11064-006-9166-z","article-title":"Neuroprotective effects of (\u2212)-epigallocatechin-3-gallate in a transgenic mouse model of amyotrophic lateral sclerosis","volume":"31","author":"Xu","year":"2006","journal-title":"Neurochem. Res."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.neulet.2005.10.056","article-title":"The effect of epigallocatechin gallate on suppressing disease progression of ALS model mice","volume":"395","author":"Koh","year":"2006","journal-title":"Neurosci. Lett."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.joim.2018.07.001","article-title":"Bioavailable curcumin formulations: A review of pharmacokinetic studies in healthy volunteers","volume":"16","author":"Jamwal","year":"2018","journal-title":"J. Integr. Med."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/12\/3056\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:00:38Z","timestamp":1760187638000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/12\/3056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,22]]},"references-count":119,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2019,6]]}},"alternative-id":["ijms20123056"],"URL":"https:\/\/doi.org\/10.3390\/ijms20123056","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,22]]}}}